Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CERS
CERS logo

CERS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.870
1 Day change
2.75%
52 Week Range
2.960
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cerus Corp (CERS) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company shows revenue growth, its financial performance is weak with declining net income and gross margin. Insider selling is significantly high, and there are no recent positive news catalysts or strong trading signals. The technical indicators are neutral, and the options data suggests low bullish sentiment. Therefore, holding off on buying this stock is recommended at this time.

Technical Analysis

The MACD histogram is positive and expanding, indicating slight bullish momentum. RSI is neutral at 50, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support is at 1.662, and resistance is at 1.903, with the current price of 1.85 sitting near resistance levels.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • Revenue increased by 13.79% YoY in Q4 2025, indicating some growth in the company's operations.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 2149.61% increase in selling activity over the last month. Net income declined by -13.37% YoY, and gross margin dropped by -3.54% YoY. No recent news or significant trading trends from hedge funds. No recent congress trading data.

Financial Performance

In Q4 2025, revenue increased to $64.58M (up 13.79% YoY), but net income dropped to -$2.18M (-13.37% YoY). EPS remained negative at -0.01. Gross margin decreased to 56.64% (-3.54% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available for evaluation.

Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
Wall Street analysts forecast CERS stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.820
sliders
Low
4
Averages
4.5
High
5
Current: 1.820
sliders
Low
4
Averages
4.5
High
5
TD Cowen
TD Cowen
Buy
maintain
$5
AI Analysis
2025-12-23
Reason
TD Cowen
TD Cowen
Price Target
$5
AI Analysis
2025-12-23
maintain
Buy
Reason
TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.

People Also Watch